POverview
Protara Therapeutics operates as a clinical-stage biopharmaceutical company focused on therapies for cancer and rare diseases, funded by public markets with a cash runway into 2027. Lead asset TARA-002 is an immunopotentiator cell therapy derived from Streptococcus pyogenes, designed to stimulate innate and adaptive immunity in tumors, with NMIBC trials showing promising responses. A second asset, IV Choline Chloride, provides intravenous choline for IFALD in parenteral nutrition-dependent patients, aiming to be the first approved therapy and holding FDA orphan drug and fast track designations. The company distinguishes itself by pursuing late-stage assets with clear regulatory and commercialization paths, backed by leadership with biopharma and finance experience, aiming to obtain regulatory approvals and bring therapies to patients with significant unmet needs.
Work here?Claim your company
About Protara Therapeutics
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
New York City, United States
Founded
2006
Get referred to Protara Therapeutics
See people who can refer or advise you
Funding
Total Funding
$224.2M
Above
Industry Average
Funded Over
4 Rounds
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- 401(k) Company Match
- Unlimited Paid Time Off
- Flexible Work Hours
- Paid Holidays
- Commuter Benefits
- Fertility Treatment Support
Stock Price
Company News
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William “Bill” Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara.“It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “With an impressive track record building commercial organizations and successfully launching oncology and rare disease products, his strategic insights will ensure the Company is well-positioned for its potential transition into a commercial-stage organization.”“With a potentially best-in-class bladder cancer therapy and two de-risked rare disease programs, Protara has the opportunity to meaningfully impact patient outcomes,” said Mr. Conkling. “I look forward to working alongside the talented Protara team as we prepare for the next phase of growth.”Mr
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies.“We are delighted to welcome Dr. Nicacio to the Protara team,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “As a proven leader with deep expertise spanning all stages of drug development, his guidance and insight will be invaluable as we advance our therapeutic candidates for patients impacted by some of the most underserved cancers and rare diseases.”Dr
Protara secures major funding through $6.25/share offering and pre-funded warrants. Proceeds to accelerate TARA-002 clinical development and expand pipeline programs.
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 2:00 pm ET in Boston.A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.About Protara Therapeutics, Inc.Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:00 pm ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs)
Protara Therapeutics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About Protara Therapeutics
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
New York City, United States
Founded
2006
Protara Therapeutics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs